logo
  

Pre-market Movers: IMUX, ARC, SNAP, VRE, JAN…

us pre market 053119 21oct22 lt

The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.25 A.M. ET).

In the Green

ARC Document Solutions, Inc. (ARC) is up over 33% at $2.88
Veris Residential, Inc. (VRE) is up over 17% at $14.65
JanOne Inc. (JAN) is up over 15% at $2.07
Liberty Energy Inc. (LBRT) is up over 9% at $17.00
Calliditas Therapeutics AB (publ) (CALT) is up over 8% at $12.52
Nurix Therapeutics, Inc. (NRIX) is up over 8% at $11.93
Weber Inc. (WEBR) is up over 7% at $5.59
Cinemark Holdings, Inc. (CNK) is up over 6% at $9.75
Quanergy Systems, Inc. (QNGY) is up over 5% at $1.99

In the Red

Immunic, Inc. (IMUX) is down over 68% at $2.90
Snap Inc. (SNAP) is down over 26% at $7.89
Tenet Healthcare Corporation (THC) is down over 14% at $46.68
Graphite Bio, Inc. (GRPH) is down over 11% at $2.90
Robert Half International Inc. (RHI) is down over 10% at $71.56
Twitter, Inc. (TWTR) is down over 7% at $48.37
Pinterest, Inc. (PINS) is down over 7% at $21.28
SOS Limited (SOS) is down over 6% at $4.22

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
RELATED NEWS
Follow RTT